EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Gut Bacteria‐Derived Colibactin as a Driver of Early‐Onset Colorectal Cancer

Satoshi Shiba, Shinichi Yachida iD, Tatsuhiro Shibata

Cancer Science · 16.11.2026

DOI: 10.1111/cas.70590 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 16.11.2026. Verfasst von Satoshi Shiba und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Genome Informatics, Graduate School of Medicine, The University of Osaka, Osaka, Japan. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains a global threat that has yet to be conquered, and this challenge is compounded by the rising worldwide incidence of early‐onset CRC (EO‐CRC), diagnosed before age 50. Most EO‐CRC cases are sporadic and microsatellite‐stable, and their etiology has yet to be fully elucidated. “Mutational epidemiology,” which applies whole‐genome sequencing to decode mutational signatures imprinted in tumor genomes, has emerged as a powerful tool for tracing carcinogen exposures. A key discovery is colibactin, a genotoxic metabolite produced by Escherichia coli and other Enterobacteriaceae carrying the pks pathogenicity island, which generates unique mutational signatures, SBS88 and ID18. Large‐scale CRC genomic surveys, including the Mutographs Cancer Grand Challenge, show that regions with higher CRC incidence carry greater colibactin‐signature burden, and that Japanese patients, particularly those with EO‐CRC, show the highest prevalence worldwide, approximately 50%. Mechanistically, colibactin alkylates adenines within AT‐rich motifs, producing interstrand crosslinks that collapse replication forks and generate double‐strand breaks, thereby generating driver mutations in APC , TP53 , and BRAF . Notably, this mutational imprinting appears to occur predominantly early in life, whereas carcinogenesis manifests decades later, revealing a striking temporal gap between colibactin exposure and tumor onset. This review integrates global epidemiological and genomic data with the chronology of pks + bacteria to explain the spread of colibactin‐induced CRC in Japan, particularly among younger people. These insights may ultimately inform new strategies for the prevention and early detection of EO‐CRC.

Schlagwörter

Stichwörter der Autor:innen

ID18SBS88colibactinearly‐onset colorectal cancermutational signature

Autor:innen und Institutionen

  • Department of Cancer Genome Informatics, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), Tokyo, Japan.
  • Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), The University of Osaka, Osaka, Japan.
  • Laboratory of Molecular Medicine, Human Genome Center, the Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Shinichi Yachida

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Shiba, S., Yachida, S., & Shibata, T. (2026). Gut Bacteria‐Derived Colibactin as a Driver of Early‐Onset Colorectal Cancer. Cancer Science. https://doi.org/10.1111/cas.70590

Vancouver

Shiba S, Yachida S, Shibata T. Gut Bacteria‐Derived Colibactin as a Driver of Early‐Onset Colorectal Cancer. Cancer Science. 2026. doi:10.1111/cas.70590

BibTeX
@article{Shiba2026,
  author = {Shiba, Satoshi and Yachida, Shinichi and Shibata, Tatsuhiro},
  title = {Gut Bacteria‐Derived Colibactin as a Driver of Early‐Onset Colorectal Cancer},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70590}
}
Kostenlos starten →